Mutational analysis of ProTx-I and the novel venom peptide Pe1b provide insight into residues responsible for selective inhibition of the analgesic drug target NaV1.7
Darshani B. Rupasinghe(The University of Queensland), Glenn F. King(The University of Queensland), Frank Bosmans(Vrije Universiteit Brussel), Irina Vetter(Centre National de la Recherche Scientifique), Zoltan Dekan(The University of Queensland), Paul F. Alewood(The University of Queensland), Volker Herzig(University of Tübingen), John M. Gilchrist(Atara Biotherapeutics (United States)), Richard J. Lewis(AstraZeneca (Netherlands))
Cited by 14
Related Papers
A small-molecule inhibitor of the NLRP3 inflammasome for the treatment of inflammatory diseases
|Nature Medicine|2015|2.8k
Methods Used to Evaluate Pain Behaviors in Rodents
|Frontiers in Molecular Neuroscience|2017|1.3k
Therapeutic potential of venom peptides
|Nature Reviews Drug Discovery|2003|786
Pathophysiology of Chemotherapy-Induced Peripheral Neuropathy
|Frontiers in Molecular Neuroscience|2017|654
Conus Venom Peptide Pharmacology
|Pharmacological Reviews|2012|422